{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:11:20Z","timestamp":1782587480040,"version":"3.54.5"},"reference-count":61,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC-A656-5QD30"],"award-info":[{"award-number":["MC-A656-5QD30"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012176","name":"Maudsley Charity","doi-asserted-by":"publisher","award":["666"],"award-info":[{"award-number":["666"]}],"id":[{"id":"10.13039\/100012176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.euroneuro.2019.09.005","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T08:11:13Z","timestamp":1571645473000},"page":"1333-1342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Glutamatergic function in a genetic high-risk group for psychosis: A proton magnetic resonance spectroscopy study in individuals with 22q11.2 deletion"],"prefix":"10.1016","volume":"29","author":[{"given":"Maria","family":"Rogdaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Hathway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gudbrandsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1102-2566","authenticated-orcid":false,"given":"Robert A.","family":"McCutcheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Jauhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Howes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2019.09.005_bib0001","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/schbul\/sbu115","article-title":"Functional outcome in people at high risk for psychosis predicted by thalamic glutamate levels and prefronto-striatal activation","volume":"41","author":"Allen","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0002","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","article-title":"An inventory for measuring clinical anxiety: psychometric properties","volume":"56","author":"Beck","year":"1988","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0003","doi-asserted-by":"crossref","unstructured":"Beck, A.T., Steer, R.A., Brown, G.K., 1996. Beck Depression Inventory-II. San Antonio, TX, 78204\u201372498.","DOI":"10.1037\/t00742-000"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0004","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1176\/appi.ajp.2015.14101358","article-title":"Microglial activity in people at ultra high risk of psychosis and in schizophrenia: An [(11)C]PBR28 pet brain imaging study","volume":"173","author":"Bloomfield","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0920-9964(00)00017-7","article-title":"Short form of the wais-iii for use with patients with schizophrenia","volume":"46","author":"Blyler","year":"2000","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0006","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jamapsychiatry.2013.3939","article-title":"Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 t","volume":"71","author":"Bustillo","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0007","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/mp.2009.121","article-title":"1H-MRS at 4\u00a0T in minimally treated early schizophrenia","volume":"15","author":"Bustillo","year":"2010","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0008","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1086\/515508","article-title":"Molecular definition of 22q11 deletions in 151 velo-cardio-facial syndrome patients","volume":"61","author":"Carlson","year":"1997","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0009","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0006-8993(97)00721-X","article-title":"Proline-induced inhibition of glutamate release in hippocampal area CA1","volume":"769","author":"Cohen","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0010","doi-asserted-by":"crossref","first-page":"e21685","DOI":"10.1371\/journal.pone.0021685","article-title":"Proton magnetic resonance spectroscopy in 22q11 deletion syndrome","volume":"6","author":"da Silva Alves","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0011","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamapsychiatry.2013.289","article-title":"Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study","volume":"70","author":"de la Fuente-Sandoval","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0012","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/npp.2011.65","article-title":"Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis","volume":"36","author":"de la Fuente-Sandoval","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0013","first-page":"1","article-title":"Cortico-Striatal GABAergic and glutamatergic dysregulations in subjects at ultra-high risk for psychosis investigated with proton magnetic resonance spectroscopy","volume":"19","author":"de la Fuente-Sandoval","year":"2015","journal-title":"Int. J. Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0014","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fpsyt.2017.00066","article-title":"Effects of antipsychotic administration on brain glutamate in schizophrenia: A systematic review of longitudinal 1H-MRS studies","volume":"8","author":"Egerton","year":"2017","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0015","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41380-018-0082-9","article-title":"Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE)","volume":"23","author":"Egerton","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0016","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1038\/npp.2012.113","article-title":"Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia","volume":"37","author":"Egerton","year":"2012","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0017","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1038\/npp.2014.143","article-title":"Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis","volume":"39","author":"Egerton","year":"2014","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0018","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1007\/s00213-015-3979-x","article-title":"Glutamatergic markers, age, intellectual functioning and psychosis in 22q11 deletion syndrome","volume":"232","author":"Evers","year":"2015","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0019","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","article-title":"Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses","volume":"41","author":"Faul","year":"2009","journal-title":"Behav. Res. Methods"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0020","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/gim.2014.175","article-title":"Practical guidelines for managing adults with 22q11.2 deletion syndrome","volume":"17","author":"Fung","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0021","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1023\/A:1026773005303","article-title":"Hyperprolinaemia in patients with deletion (22)(q11. 2) syndrome","volume":"23","author":"Goodman","year":"2000","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0022","first-page":"119","article-title":"Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia","volume":"8","author":"Goto","year":"2012","journal-title":"Neuropsychiatr. Dis. Treat"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0023","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/jmri.21936","article-title":"Optimized glutamate detection at 3T","volume":"30","author":"Hancu","year":"2009","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0024","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1176\/appi.ajp.2011.11010160","article-title":"Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA pet imaging study","volume":"168","author":"Howes","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.schres.2009.08.012","article-title":"Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: A 1H spectroscopy study","volume":"115","author":"Keshavan","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0026","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1152\/physrev.1983.63.2.547","article-title":"Mitochondrial metabolism of glutamine and glutamate and its physiological significance","volume":"63","author":"Kovacevic","year":"1983","journal-title":"Physiol Rev"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0027","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive nmda antagonist, ketamine, in humans. psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0028","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0893-133X(94)00131-I","article-title":"Subanesthetic doses of ketamine stimulate psychosis in schizophrenia","volume":"13","author":"Lahti","year":"1995","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0029","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(09)60072-6","article-title":"Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study","volume":"373","author":"Lichtenstein","year":"2009","journal-title":"Lancet North Am. Ed."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0030","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1073\/pnas.042700699","article-title":"Genetic variation at the 22q11 PRODH2\/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia","volume":"99","author":"Liu","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0031","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/mp.2008.87","article-title":"Proton mrs in twin pairs discordant for schizophrenia","volume":"15","author":"Lutkenhoff","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0032","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/schbul\/sbr069","article-title":"Glutamate in schizophrenia: a focused review and meta-analysis of (1)H-MRS studies","volume":"39","author":"Marsman","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0033","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.schres.2005.06.020","article-title":"Short scales for measuring schizotypy","volume":"78","author":"Mason","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0034","doi-asserted-by":"crossref","first-page":"15071","DOI":"10.1038\/nrdp.2015.71","article-title":"22q11.2 deletion syndrome","volume":"1","author":"McDonald-McGinn","year":"2015","journal-title":"Nat. Rev. Dis Primers"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0035","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","article-title":"Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies","volume":"73","author":"Merritt","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0036","doi-asserted-by":"crossref","first-page":"2016S","DOI":"10.1093\/jn\/138.10.2016S","article-title":"Inborn errors of proline metabolism","volume":"138","author":"Mitsubuchi","year":"2008","journal-title":"J. Nutr."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0037","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2014.01.020","article-title":"Further evidence for high rates of schizophrenia in 22q11.2 deletion syndrome","volume":"153","author":"Monks","year":"2014","journal-title":"Schizophr Res."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0038","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/archpsyc.56.10.940","article-title":"High rates of schizophrenia in adults with velo-cardio-facial syndrome","volume":"56","author":"Murphy","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0039","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/schbul\/sbt124","article-title":"Reduced frontal glutamate\u202f+\u202fglutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia","volume":"40","author":"Natsubori","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0040","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archpsyc.1995.03950240016004","article-title":"Glutamate receptor dysfunction and schizophrenia","volume":"52","author":"Olney","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0041","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.schres.2013.12.013","article-title":"Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings","volume":"152","author":"Poels","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0042","unstructured":"Provencher, S., 2016. LCModel & LCMgui user's manual. Web site."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0043","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature12975","article-title":"A polygenic burden of rare disruptive mutations in schizophrenia","volume":"506","author":"Purcell","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0044","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.schres.2007.11.028","article-title":"Elevated 3T proton mrs glutamate levels associated with poor continuous performance test (CPT-0X) scores and genetic risk for schizophrenia","volume":"99","author":"Purdon","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/schbul\/sbt114","article-title":"Risk of mental illness in offspring of parents with schizophrenia, bipolar disorder, and major depressive disorder: a meta-analysis of family high-risk studies","volume":"40","author":"Rasic","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0046","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/hmg\/ddl443","article-title":"Involvement of hyperprolinemia in cognitive and psychiatric features of the 22q11 deletion syndrome","volume":"16","author":"Raux","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0047","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/nbm.1772","article-title":"13C MRS studies of neuroenergetics and neurotransmitter cycling in humans","volume":"24","author":"Rothman","year":"2011","journal-title":"NMR Biomed."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0048","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Ripke","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0049","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1176\/appi.ajp.2013.13070864","article-title":"Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the international consortium on brain and behavior in 22q11.2 deletion syndrome","volume":"171","author":"Schneider","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0050","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/hmg\/9.4.489","article-title":"Chromosome 22-specific low copy repeats and the 22q11.2 deletion syndrome: genomic organization and deletion endpoint analysis","volume":"9","author":"Shaikh","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0051","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.biopsych.2009.05.006","article-title":"Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume","volume":"66","author":"Stone","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0052","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.schres.2013.05.024","article-title":"Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy","volume":"148","author":"Tandon","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0053","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.biopsych.2016.04.007","article-title":"7T Proton magnetic resonance spectroscopy of gamma-aminobutyric acid, glutamate, and glutamine reveals altered concentrations in patients with schizophrenia and healthy siblings","volume":"81","author":"Thakkar","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0054","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1176\/appi.ajp.159.11.1944","article-title":"Glutamate and glutamine measured with 4.0 t proton mrs in never-treated patients with schizophrenia and healthy volunteers","volume":"159","author":"Theberge","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0055","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1176\/appi.ajp.161.6.1116","article-title":"3-T proton mrs investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia","volume":"161","author":"Tibbo","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0056","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/mrm.24291","article-title":"3-T proton magnetic spectroscopy in unmedicated first episode psychosis: a focus on creatine","volume":"69","author":"Tibbo","year":"2013","journal-title":"Magn. Reson. Med."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0057","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.schres.2016.01.005","article-title":"Are there glutamate abnormalities in subjects at high risk mental state for psychosis? a review of the evidence","volume":"171","author":"Treen","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0058","series-title":"WAIS-III, Wechsler adult Intelligence scale: Administration and Scoring Manual","author":"Wechsler","year":"1997"},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0059","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.neubiorev.2015.01.007","article-title":"In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophrenia","volume":"51","author":"Wijtenburg","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0060","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.schres.2009.03.036","article-title":"Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus","volume":"111","author":"Yoo","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2019.09.005_bib0061","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/j.1440-1614.2005.01714.x","article-title":"Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states","volume":"39","author":"Yung","year":"2005","journal-title":"Aust. N. Z. J. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X1930879X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X1930879X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T21:13:12Z","timestamp":1777583592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X1930879X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0924977X1930879X"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2019.09.005","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glutamatergic function in a genetic high-risk group for psychosis: A proton magnetic resonance spectroscopy study in individuals with 22q11.2 deletion","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2019.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}